Skip to content
Review Open access

Pancytopenia and isolated cytopenias as hematological complications of SLE: A narrative review.

Sep 2026 · Advances in Clinical and Experimental Medicine · Vol 35, pp. 1653-1664 · 0 citations
Medicine

TL;DR

This review aims to summarize and synthesize current knowledge on the etiology, pathophysiology, diagnostic approach, and treatment strategies for pancytopenia in SLE, as well as its differentiation from other causes of bone marrow failure.

Abstract

Pancytopenia is a significant hematological complication in patients with systemic lupus erythematosus (SLE), with an estimated prevalence of 10-40%. It is defined as a simultaneous decrease in red blood cells, white blood cells, and platelets. Although isolated cytopenias are more common, pancytopenia may indicate severe disease activity or secondary complications, such as bone marrow suppression or hemophagocytic syndromes. This review aims to summarize and synthesize current knowledge on the etiology, pathophysiology, diagnostic approach, and treatment strategies for pancytopenia in SLE, as well as its differentiation from other causes of bone marrow failure. The pathogenesis of pancytopenia in SLE is multifactorial and includes drug-induced bone marrow suppression, hypersplenism, myelofibrosis, macrophage activation syndrome (MAS), and autoimmune bone marrow failure. The diagnostic evaluation includes hematologic assessment, bone marrow examination, and exclusion of alternative diagnoses, such as aplastic anemia and paroxysmal nocturnal hemoglobinuria. Therapeutic management depends on the underlying cause. We also summarize published case reports comparing treatment approaches and clinical outcomes. The role of rituximab (RTX) in the management of pancytopenia and isolated cytopenias associated with SLE is discussed in detail. Particular attention is given to its mechanisms of action, safety profile and mixed clinical outcomes, documented in multicenter retrospective cohort studies, meta-analyses, and case series. Early recognition of pancytopenia remains a clinical challenge and requires well-structured diagnostic and therapeutic strategies. A thorough understanding of its underlying mechanisms and clinical manifestations is essential to avoid delays in treatment and prevent complications.

Read PDF

Similar papers

Open access Oct 2026

Study on clinical and haematological profile of pancytopenia with special reference to bone marrow picture

Background: Pancytopenia is a hematological condition characterized by the simultaneous reduction of red blood cells, white blood cells, and platelets. It represents a manifestation of various underlying disorders, ranging from nutritional deficiencies to hematological malignancies. Understanding the clinical and hemat...

P. S., Rohith C. · 0 citations
Review Open access Oct 2026

Hepatitis-Associated Aplastic Anemia in Children and Adolescents: A Comprehensive Review.

Hepatitis-associated aplastic anemia (HAAA) is a rare but life-threatening subtype of acquired aplastic anemia (AA) that predominantly affects children and adolescents, characterized by bone marrow failure developing weeks to months following acute hepatitis. Although HAAA accounts for a small proportion of AA cases, i...

Emily Liao, Shova Subedi, V. Kasper et al. · 0 citations
Open access Sep 2026

Hemophagocytic Syndrome Associated with Infectious Diseases in Pancytopenic Dogs

#These authors contributed equally to this work. Background: Pancytopenia, characterized by a reduction in the number of peripheral blood cells, encompasses various etiologies, including infectious, immune-mediated diseases, sepsis and drug-related causes. The primary diagnostic tool for pancytopenia is bone marrow asp...

M. Ranjithkumar, V. Arvind, N. Pazhanivel et al. · 0 citations
Case report Open access Oct 2026

Iptacopan combined with immunosuppressive therapy for aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome

Iptacopan served as a bridge to control hemolysis, while the subsequent addition of IST addressed the underlying autoimmune bone marrow failure and no breakthrough hemolysis, extravascular hemolysis, or drug-related adverse events were observed.

Xiao-Qian Liu, Jie Xu, Ya-Qin Luo et al. · 0 citations
Open access Oct 2026

Clinicohematological Profile of Patients With Pancytopenia in A Tertiary Care Hospital in Western India

A systematic evaluation of the clinical profile, hematological findings, bone marrow morphology, and etiological spectrum of pancytopenia in patients attending a tertiary care hospital in Western India highlighted the continued burden of nutritional deficiencies.

J. Bora, S. Christian, A. Agravat et al. · 0 citations
Open access Sep 2026

Autoimmune hemolytic anemia associated with multiple myeloma: a rare case report

Background. Autoimmune hemolytic anemia (AIHA) is characterized by autoantibodies binding to red blood cell antigens, leading to hemolysis through complement activation and the reticuloendothelial system. It is commonly associated with B-cell lymphoproliferative disorders, while its occurrence in multiple myeloma (MM)...

Erni Mariana Tjahyadi, P. B. Notopuro, Wahyu Setiani Wibowo · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.